imiquimod has been researched along with thalidomide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Sondak, VK | 1 |
| Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK | 1 |
| Alalaiwe, A; Fang, JY; Lin, ZC; Tang, KW; Tseng, CH; Wang, PW | 1 |
| Egawa, S; Ito, M; Kamata, M; Mizukawa, I; Shimizu, T; Tada, Y; Takeshima, R; Uchida, H; Watanabe, A | 1 |
| Bansal, AK; Parmar, PK; Rohit, A; Sharma, N; Wasil Kabeer, S | 1 |
6 other study(ies) available for imiquimod and thalidomide
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Advances in the understanding and treatment of melanoma -- Keystone Symposium.
Topics: Aminoquinolines; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Humans; Imiquimod; Immunotherapy; Melanoma; Neoplasm Staging; Thalidomide; Toll-Like Receptors | 2006 |
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Topics: Acitretin; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Imiquimod; Mice, Inbred BALB C; Microvessels; Neovascularization, Pathologic; Psoriasis; Signal Transduction; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Keratinocytes; Male; MAP Kinase Signaling System; Mice; NF-kappa B; Phosphorylation; Psoriasis; Skin; Thalidomide; Transcription Factor AP-1; Tumor Necrosis Factor-alpha | 2020 |
Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis.
Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Interleukin-17; Mice; Psoriasis; Spleen; T-Lymphocytes, Regulatory; Thalidomide | 2021 |
Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses.
Topics: Animals; Disease Models, Animal; Gels; Imiquimod; Nanoparticles; Psoriasis; Skin; Thalidomide | 2022 |